Ascendiant Capital Markets initiated coverage on shares of Envoy Medical (NASDAQ:COCH – Free Report) in a research report report published on Monday, Marketbeat reports. The brokerage issued a buy rating and a $8.50 price objective on the stock.
Separately, Lake Street Capital increased their price objective on Envoy Medical from $3.00 to $6.00 and gave the company a buy rating in a research report on Wednesday, April 3rd.
View Our Latest Stock Report on COCH
Envoy Medical Price Performance
Envoy Medical (NASDAQ:COCH – Get Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.13). The company had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.08 million. Equities research analysts predict that Envoy Medical will post -1.05 EPS for the current fiscal year.
Hedge Funds Weigh In On Envoy Medical
Institutional investors and hedge funds have recently made changes to their positions in the business. WealthTrust Asset Management LLC purchased a new stake in Envoy Medical during the first quarter valued at about $44,000. Virtu Financial LLC purchased a new position in shares of Envoy Medical in the first quarter worth about $55,000. Finally, Weiss Asset Management LP bought a new stake in shares of Envoy Medical in the 4th quarter valued at about $37,000. Institutional investors own 8.59% of the company’s stock.
About Envoy Medical
Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.
Read More
- Five stocks we like better than Envoy Medical
- Buy P&G Now, Before It Sets A New All-Time High
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- Which Wall Street Analysts are the Most Accurate?
- Progress Software Stock Back in the Green After Beating Forecasts
- Best Aerospace Stocks Investing
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Envoy Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envoy Medical and related companies with MarketBeat.com's FREE daily email newsletter.